Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,622,721
  • Shares Outstanding, K 19,941
  • Annual Sales, $ 268,090 K
  • Annual Income, $ 124,450 K
  • EBIT $ 74 M
  • EBITDA $ 104 M
  • 60-Month Beta 1.14
  • Price/Sales 16.61
  • Price/Cash Flow 28.43
  • Price/Book 4.32

Options Overview Details

View History
  • Implied Volatility 47.24% (-0.72%)
  • Historical Volatility 44.72%
  • IV Percentile 87%
  • IV Rank 41.33%
  • IV High 73.14% on 04/13/26
  • IV Low 28.98% on 08/08/25
  • Expected Move (DTE 25) 7.23 (3.11%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 13
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 1,067
  • Open Int (30-Day) 1,076
  • Expected Range 225.02 to 239.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.01
  • Number of Estimates 3
  • High Estimate $1.37
  • Low Estimate $0.63
  • Prior Year $-2.21
  • Growth Rate Est. (year over year) +145.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.67 +22.85%
on 03/30/26
234.76 -1.27%
on 04/14/26
+26.97 (+13.17%)
since 03/20/26
3-Month
178.72 +29.69%
on 02/26/26
234.76 -1.27%
on 04/14/26
+35.22 (+17.92%)
since 01/20/26
52-Week
98.89 +134.38%
on 05/30/25
234.76 -1.27%
on 04/14/26
+126.81 (+120.81%)
since 04/17/25

Most Recent Stories

More News
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER,...

TVTX : 40.29 (-1.18%)
LGND : 231.78 (-0.02%)
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown...

LGND : 231.78 (-0.02%)
Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...

LGND : 231.78 (-0.02%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 231.78 (-0.02%)
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Robust financial performance driven by full year 2025 royalty revenue growth of  48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share...

LGND : 231.78 (-0.02%)
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday,...

LGND : 231.78 (-0.02%)
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will...

LGND : 231.78 (-0.02%)
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

LGND : 231.78 (-0.02%)
KNSA : 42.46 (-5.43%)
ASND : 245.38 (+0.37%)
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over...

LGND : 231.78 (-0.02%)
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from...

LGND : 231.78 (-0.02%)
MDT : 85.00 (-1.38%)
OBIO : 4.35 (-5.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 244.95
2nd Resistance Point 239.63
1st Resistance Point 235.73
Last Price 231.78
1st Support Level 226.50
2nd Support Level 221.18
3rd Support Level 217.28

See More

52-Week High 234.76
Last Price 231.78
Fibonacci 61.8% 182.86
Fibonacci 50% 166.82
Fibonacci 38.2% 150.79
52-Week Low 98.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.